Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02200380 · ClinicalTrials.gov registry record · Phase 2
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
A Phase 2 study, sponsored by Celldex Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT02200380 is a Phase 2 study that was terminated before completion, run by Celldex Therapeutics. The registered enrollment target is 36 participants.
The verdict
NCT02200380, a Phase 2 study, was terminated before completion, sponsored by Celldex Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person). HLA-matched sibling healthy volunteers (donors) and patients with protocol specified hematologic malignancies (recipients) will be enrolled.
Interventions
- DRUG CDX-301
- DRUG CDX-301 and plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-04-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02200380
The ClinicalTrials.gov registry entry for NCT02200380 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CDX-301 is the first listed.
NCT02200380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02200380 about?
NCT02200380 is a clinical study titled "A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs". This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person). HLA-matched sibling healthy volunteers (donors) and patients with protocol specified hematologic malig...
What is the current status of trial NCT02200380?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2014-07. Estimated completion is 2016-04-13.
What interventions are being tested in trial NCT02200380?
The interventions under investigation include: CDX-301 (DRUG), CDX-301 and plerixafor (DRUG).
Who is sponsoring clinical trial NCT02200380?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.